Kura Oncology Inc Dossier
Qualitative Analysis
Business overview
Kura Oncology, Inc. is a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer. The company's pipeline consists of small molecule drug candidates designed to target cancer signaling pathways and address high-need hematologic malignancies and solid tumors. Kura's flagship product is KOMZIFTI™ (ziftomenib), a once-daily, oral menin inhibitor approved by the FDA in November 2025 for the treatment of adults with relapsed or refractory (R/R) NPM1-mutated acute myeloid leukemia (AML). Beyond hematologic malignancies, Kura is advancing a pipeline of targeted therapies, including darlifarnib (a farnesyl transferase inhibitor) and KO-7246 (a next-generation menin inhibitor).
Research as of 19 Jun 2026
Strategic Initiatives
Growth programs, investments, and their expected impact
Driving rapid adoption and commercial uptake of KOMZIFTI (ziftomenib) in the U.S. for relapsed or refractory NPM1-mutated AML, focusing on expanding payer coverage and repeat prescribing across activated clinical accounts.
Expected impact: Aims to capture a leading share of the $350 million to $400 million relapsed/refractory NPM1-mutant AML market opportunity.
Advancing ziftomenib into earlier lines of therapy by evaluating it in combination with standard-of-care regimens (such as venetoclax, azacitidine, and intensive/non-intensive chemotherapy) through the Phase 3 KOMET-017 and Phase 1b KOMET-007 trials.
Expected impact: Positions ziftomenib as a foundational frontline therapy, expanding the addressable patient population to more than 50% of all AML cases.
Expanding the clinical pipeline beyond hematology by developing farnesyl transferase inhibitors (FTIs), specifically darlifarnib (KO-2806) and tipifarnib, in combination with other targeted therapies (such as adagrasib and cabozantinib) for large solid tumor indications including renal cell carcinoma (RCC) and KRAS-mutated cancers.
Expected impact: Addresses a potential combined patient population of more than 200,000 patients across diverse solid tumor indications.
Mergers, Acquisitions & Partnerships
Recent deals and strategic collaborations
Strategic Partnerships
Co-development and co-commercialization of ziftomenib in AML and other hematologic malignancies, providing global scale, commercial expertise, and substantial non-dilutive funding.
Terms: Kura received a $330 million upfront payment and is eligible for up to $1.2 billion in total milestone payments (including $420 million in near-term milestones). The companies share U.S. profits and losses 50:50, with Kura booking U.S. sales. Kura funds global development through 2028, with a 50:50 cost-share starting in 2029.